Researcher charged in major HIV vaccine fraud case

by Ryan J. Foley

Responding to a major case of research misconduct, federal prosecutors are taking a rare step by charging a scientist with fraud after he admitted falsifying data while researching an HIV vaccine.

Authorities say former Iowa State University laboratory manager Dong-Pyou Han has confessed to manipulating data that helped his team get millions in grants and increased hopes of a major breakthrough in AIDS research.

Experts say the was particularly brazen, and charges are rarely brought in part because less money is usually involved. The National Institutes of Health is reviewing the case's impact on research it funds.

Han resigned from the university last fall. He was indicted last week and could face prison time if convicted. He's free on bond but didn't respond to a message seeking comment Tuesday.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Court sides with US in cell-tracking records case (Update)

May 09, 2014

The Justice Department does not have to turn over information on cases involving warrantless cellphone tracking if the cases ended without a defendant's conviction, a divided U.S. appeals court ruled Friday in upholding privacy ...

UK researcher sentenced to three months' jail for faking data

Apr 19, 2013

A British scientist convicted of scientific fraud last month for falsifying research data has been sentenced to three months jail. Steven Eaton is the first person to serve time under the UK's Good Laboratory Practice Regulations, 1999. ...

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments